Eden will set up an optimized biomanufacturing process before proceeding with clinical trial cGMP manufacture for Hep A and B combined vaccine.
Eden Biodesign and iQur signed an agreement to help iQur further its tandem core vaccine for hepatitis A and B. Eden will will develop a biomanufacturing process to achieve optimal product quality in line with cost of goods parameters before proceeding with clinical trial cGMP manufacture.
According to iQur, its vaccine platform based on the HBV core protein can carry antigens specific for both hepatitis A and B simultaneously. Furthermore, the construct is highly immunogenic and should dramatically increase vaccine efficiency and reduce the current need for booster vaccinations, explains Mike Whelan, head of scientific operations at iQur.
The project will also involve iQur’s collaborators, Arecor, Mologic, and the University of Leeds.
